183 related articles for article (PubMed ID: 2556078)
1. Treatment of experimental cryptococcal meningitis and disseminated candidiasis with SCH39304.
Perfect JR; Wright KA; Hobbs MM; Durack DT
Antimicrob Agents Chemother; 1989 Oct; 33(10):1735-40. PubMed ID: 2556078
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of SCH39304 in murine cryptococcosis.
Restrepo BI; Ahrens J; Graybill JR
Antimicrob Agents Chemother; 1989 Aug; 33(8):1242-6. PubMed ID: 2552903
[TBL] [Abstract][Full Text] [Related]
3. Comparison of itraconazole and fluconazole in treatment of cryptococcal meningitis and candida pyelonephritis in rabbits.
Perfect JR; Savani DV; Durack DT
Antimicrob Agents Chemother; 1986 Apr; 29(4):579-83. PubMed ID: 3010846
[TBL] [Abstract][Full Text] [Related]
4. The pharmacokinetics of BAY R3783 and its efficacy in the treatment of experimental cryptococcal meningitis.
Wright KA; Perfect JR; Ritter W
J Antimicrob Chemother; 1990 Sep; 26(3):387-97. PubMed ID: 2172199
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans.
Perfect JR; Cox GM; Dodge RK; Schell WA
Antimicrob Agents Chemother; 1996 Aug; 40(8):1910-3. PubMed ID: 8843302
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis, and cryptococcosis.
Hata K; Kimura J; Miki H; Toyosawa T; Moriyama M; Katsu K
Antimicrob Agents Chemother; 1996 Oct; 40(10):2243-7. PubMed ID: 8891122
[TBL] [Abstract][Full Text] [Related]
7. Discovery of New Tricyclic Oxime Sampangine Derivatives as Potent Antifungal Agents for the Treatment of Cryptococcosis and Candidiasis.
Yang W; Liu R; Li Z; Tu J; Xu D; Liu N; Sheng C
J Med Chem; 2024 Mar; 67(6):4726-4738. PubMed ID: 38489247
[No Abstract] [Full Text] [Related]
8. Fluconazole therapy for experimental cryptococcosis and candidiasis in the rabbit.
Perfect JR
Rev Infect Dis; 1990; 12 Suppl 3():S299-302. PubMed ID: 2184508
[TBL] [Abstract][Full Text] [Related]
9. Efficacies of high-dose fluconazole plus amphotericin B and high-dose fluconazole plus 5-fluorocytosine versus amphotericin B, fluconazole, and 5-fluorocytosine monotherapies in treatment of experimental endocarditis, endophthalmitis, and pyelonephritis due to Candida albicans.
Louie A; Liu W; Miller DA; Sucke AC; Liu QF; Drusano GL; Mayers M; Miller MH
Antimicrob Agents Chemother; 1999 Dec; 43(12):2831-40. PubMed ID: 10582868
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo antifungal activities of T-2307, a novel arylamidine.
Mitsuyama J; Nomura N; Hashimoto K; Yamada E; Nishikawa H; Kaeriyama M; Kimura A; Todo Y; Narita H
Antimicrob Agents Chemother; 2008 Apr; 52(4):1318-24. PubMed ID: 18227186
[TBL] [Abstract][Full Text] [Related]
11. Oral fluconazole therapy for patients with acquired immunodeficiency syndrome and cryptococcosis: experience with 22 patients.
Stern JJ; Hartman BJ; Sharkey P; Rowland V; Squires KE; Murray HW; Graybill JR
Am J Med; 1988 Oct; 85(4):477-80. PubMed ID: 2845778
[TBL] [Abstract][Full Text] [Related]
12. [Clinical evaluation of fluconazole].
Oka S; Tokitsu M; Mori H; Nakata H; Goto M; Goto H; Shimada K
Jpn J Antibiot; 1989 Jan; 42(1):31-9. PubMed ID: 2540365
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum.
Hata K; Kimura J; Miki H; Toyosawa T; Nakamura T; Katsu K
Antimicrob Agents Chemother; 1996 Oct; 40(10):2237-42. PubMed ID: 8891121
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo efficacies of the new triazole albaconazole against Cryptococcus neoformans.
Miller JL; Schell WA; Wills EA; Toffaletti DL; Boyce M; Benjamin DK; Bartroli J; Perfect JR
Antimicrob Agents Chemother; 2004 Feb; 48(2):384-7. PubMed ID: 14742184
[TBL] [Abstract][Full Text] [Related]
15. Treatment of murine coccidioidal meningitis with SCH39304.
Defaveri J; Sun SH; Graybill JR
Antimicrob Agents Chemother; 1990 Apr; 34(4):663-4. PubMed ID: 2160794
[TBL] [Abstract][Full Text] [Related]
16. Development of azole resistance during fluconazole maintenance therapy for AIDS-associated cryptococcal disease.
Friese G; Discher T; Füssle R; Schmalreck A; Lohmeyer J
AIDS; 2001 Nov; 15(17):2344-5. PubMed ID: 11698718
[No Abstract] [Full Text] [Related]
17. Repurposing and Reformulation of the Antiparasitic Agent Flubendazole for Treatment of Cryptococcal Meningoencephalitis, a Neglected Fungal Disease.
Nixon GL; McEntee L; Johnson A; Farrington N; Whalley S; Livermore J; Natal C; Washbourn G; Bibby J; Berry N; Lestner J; Truong M; Owen A; Lalloo D; Charles I; Hope W
Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29311092
[TBL] [Abstract][Full Text] [Related]
18. Pulmonary aspergillosis in mice: treatment with a new triazole SCH39304.
Defaveri J; Salazar MH; Rinaldi MG; Graybill JR
Am Rev Respir Dis; 1990 Sep; 142(3):512-5. PubMed ID: 2202244
[TBL] [Abstract][Full Text] [Related]
19. Penetration of new azole compounds into the eye and efficacy in experimental Candida endophthalmitis.
Savani DV; Perfect JR; Cobo LM; Durack DT
Antimicrob Agents Chemother; 1987 Jan; 31(1):6-10. PubMed ID: 3032091
[TBL] [Abstract][Full Text] [Related]
20. Invasive fungal infection by Cryptococcus neoformans var. grubii with bone marrow and meningeal involvement in a HIV-infected patient: a case report.
Vechi HT; Theodoro RC; de Oliveira AL; Gomes RMODS; Soares RDA; Freire MG; Bay MB
BMC Infect Dis; 2019 Mar; 19(1):220. PubMed ID: 30832607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
